Severe steroid refractory gastritis induced by Nivolumab: A case report

BACKGROUND: Immune checkpoint inhibitors are widely used for treatment of many advanced malignancies. Lower gastrointestinal (GI) side effects, such as diarrhea and colitis, are common, but upper GI side effects are rarely reported. Consequently, the correct treatment of upper GI adverse events has...

Descripción completa

Detalles Bibliográficos
Autores principales: Vindum, Helene Hjorth, Agnholt, Jørgen S, Nielsen, Anders Winther Moelby, Nielsen, Mette Bak, Schmidt, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201147/
https://www.ncbi.nlm.nih.gov/pubmed/32390707
http://dx.doi.org/10.3748/wjg.v26.i16.1971
Descripción
Sumario:BACKGROUND: Immune checkpoint inhibitors are widely used for treatment of many advanced malignancies. Lower gastrointestinal (GI) side effects, such as diarrhea and colitis, are common, but upper GI side effects are rarely reported. Consequently, the correct treatment of upper GI adverse events has been less frequently described. CASE SUMMARY: We describe a case of a 16-year-old woman with stage IIIb malignant melanoma treated with adjuvant monotherapy using Nivolumab. The patient developed severe gastritis after six series of Nivolumab with weight loss, nausea, and vomiting. There was no effect of intravenous steroids, but the patient´s condition resolved after administration of Infliximab. CONCLUSION: This case report supports the same treatment for gastritis as for colitis, which is in line with current guidelines.

Ejemplares similares